IBL-302
IBL-302 (AMU302) is an orally available dual-signaling inhibitor of PIM and PI3K/AKT/mTOR with activity against breast cancer and neuroblastoma. IBL-302 demonstrated in vivo efficacy in a nude mouse xenograft model, inhibiting trastuzumab resistance challenges. IBL-302 also enhances the effects of common cytotoxic chemotherapy drugs cisplatin (HY-17394), doxorubicin (HY-15142A), and etoposide (HY-13629)[2][3].
Product Specifications
CAS Number
1414455-21-2
Product Name Alternative
AMU302
UNSPSC
12352005
Target
Akt; mTOR; PI3K; Pim
Type
Reference compound
Related Pathways
JAK/STAT Signaling; PI3K/Akt/mTOR
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/ibl-302.html
Purity
98.21
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CC1=C(C(C=C2N[S](=O)(C(C=C3)=C4)=O)=CN=C2OC)SC5=C1N=CN=C5C6=CC=C(CNC(C4=C3F)=O)S6
Molecular Formula
C25H18FN5O4S3
Molecular Weight
567.63
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
PPAR alpha (PPARA) (NM_005036) Human Over-expression Lysate
